GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently undervalued according to InvestingPro Fair Value metrics, has reached a ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I reiterate strong buy rating on GSK stock.

GSK plc announced that the European Medicines ... multi-centre phase III clinical trials. The trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 adult and ...

LONDON - GSK plc (LSE/NYSE ... on the positive outcomes of the SWIFT and ANCHOR phase III clinical trials. In the SWIFT trials, depemokimab demonstrated a significant reduction in exacerbation ...

GSK plc announced that new drug applications ... multi-centre phase III clinical trials.1 The trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 adult and ...

GSK plc (LSE/NYSE ... is based on the promising results from the SWIFT and ANCHOR clinical trials. If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing ...

GSK plc (LSE/NYSE: GSK ... multi-centre Phase III clinical trials. 1 The trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 adult and adolescent participants with ...

LONDON - GSK plc (LSE/NYSE: LON ... The filings are based on the positive outcomes of the SWIFT and ANCHOR phase III clinical trials. In the SWIFT trials, depemokimab demonstrated a significant ...

1-3 In asthma patients and patients with CRSwNP, these trials showed depemokimab could offer sustained inhibition of a key driver of their disease, and help achieve key clinical outcomes with a ...